-
Medicure achieved a ranking asA 2016 TSX Venture 50 Company -
Medicure Focuses OnAcute CareHospital Products
-
FDA APPROVES
Aggrastat HDB
The high-dose bolus (HDB) dosing regimen has been added to the Aggrastat (tirofiban HCI) Prescribing Information. -
medicure is traded
on TSX Venture (MPH)The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).
